The treatment outcomes for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients have improved since the introduction of Rituxan/MabThera (rituximab; Biogen Idec/Genentech/Roche/Chugai/Zenyaku Kogyo). However, an unmet need remains for novel agents with improved efficacy and toxicity profiles, particularly in the treatment of relapsed and refractory patients.
Scope
- Analysis of the DLBCL and FL market based on a survey of 180 non-Hodgkin's lymphomas specialists, supported by interviews with key opinion leaders
- Forecast of the DLBCL and FL patient populations in the seven major pharmaceutical markets
- In-depth analysis of treatment patterns, regimens prescribed and treatment outcomes for DLBCL and FL patients
- Discussion of unmet needs and overview of late-stage pipeline drugs and marketed drugs investigated for expansion into the DLBCL and FL settings
Highlights of this title
Treatment of DLBCL patients with Rituxan has increased cure rates. However, relapsed/refractory patients who are ineligible for stem cell transplant and patients who relapse following transplantation continue to have a poor prognosis. The drugs currently in late Phase development for DLBCL are expected to have minimal impact on patient prognosis.
Current treatment options in advanced FL are rarely curative but Rituxan has been shown to improve prognosis. Patients with advanced disease inevitably relapse and require further treatment. A need remains for novel therapies in the treatment of relapsed/refractory FL to improve survival rates in this hard-to-treat patient population.
The combination of Treanda (bendamustine) with Rituxan has a favorable toxicity profile and has been shown to be effective in the treatment of low-grade NHL. Recent promising clinical trial results suggest that this drug combination has the potential to become a standard of care in the treatment of patients with FL.
Key reasons to purchase this title
- Understand prescribing trends in the DLBCL and FL markets
- Examine unmet need within the DLBCL and FL markets and identify opportunities for new product development
- Enhance commercial positioning by increasing understanding of current dynamics within the DLBCL and FL markets
